Literature DB >> 16770317

Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation.

Y Caliskan1, S K Besisik, D Sargin, T Ecder.   

Abstract

Renal insufficiency is a common complication early after hematopoietic stem cell transplantation (HSCT). Renal function as measured by creatinine clearance (CrCl) was prospectively evaluated in 47 patients undergoing allogeneic (n=22) or autologous (n=25) HSCT during the first 100 days. Renal dysfunction was classified as follows: Grade 0 (<25% decline in CrCl), Grade 1 (>or=25% decline in CrCl but <2 x increase in serum creatinine), Grade 2 (>or=2 x rise in serum creatinine but no need for dialysis) and Grade 3 (>or=2 x rise in serum creatinine and need for dialysis). Thirty-three patients (70%) had Grade 1-3 renal dysfunction. Renal dysfunction was more common after myeloablative allogeneic HSCT (91%) than autologous HSCT (52%) (P=0.004), and was associated with a high risk of mortality (P=0.039). Sepsis in autologous HSCT patients and cyclosporine toxicity in allogeneic HSCT patients were associated with renal dysfunction. We conclude that autologous and allogeneic HSCT differ in the likelihood and causes of renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770317     DOI: 10.1038/sj.bmt.1705412

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

Review 1.  Acute kidney injury in hematopoietic cell transplantation.

Authors:  Amy Kogon; Sangeeta Hingorani
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

2.  Comparison of conditioning regimens for alveolar macrophage reconstitution and innate immune function post bone marrow transplant.

Authors:  Leah L N Hubbard; Megan N Ballinger; Carol A Wilke; Bethany B Moore
Journal:  Exp Lung Res       Date:  2008-06       Impact factor: 2.459

3.  An autopsy case that manifested no convincing histological changes of severe renal failure after hematopoietic stem cell transplantation.

Authors:  Kosuke Honda; Minoru Ando; Masaharu Tsubokura; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  CEN Case Rep       Date:  2013-06-06

4.  Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Authors:  S R Kanduri; W Cheungpasitporn; C Thongprayoon; T Bathini; K Kovvuru; V Garla; J Medaura; P Vaitla; K B Kashani
Journal:  QJM       Date:  2020-09-01

5.  Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.

Authors:  Michael Choi; Can-Lan Sun; Seira Kurian; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 6.  Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Authors:  Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-13       Impact factor: 8.237

Review 7.  Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review.

Authors:  Vinod Krishnappa; Mohit Gupta; Gurusidda Manu; Shivani Kwatra; Osei-Tutu Owusu; Rupesh Raina
Journal:  Int J Nephrol       Date:  2016-11-03

8.  Acute kidney injury and mortality in hematopoietic stem cell transplantation: A single-center experience.

Authors:  B Sehgal; P George; M J John; C Samuel
Journal:  Indian J Nephrol       Date:  2017 Jan-Feb

9.  Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review.

Authors:  Juliana Bastoni da Silva; Maria Helena de Melo Lima; Sílvia Regina Secoli
Journal:  Rev Bras Hematol Hemoter       Date:  2014-04-03

10.  A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Authors:  Maria Tavakoli Ardakani; Ali Tafazoli; Mahshid Mehdizadeh; Abbas Hajifathali; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.